Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FULC Stock Forecast 2025-2026
$6.25
Current Price
$351.41M
Market Cap
Buy 3
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to FULC Price Targets
+92.0%
To High Target of $12.00
-36.0%
To Median Target of $4.00
-68.0%
To Low Target of $2.00
FULC Price Momentum
-5.3%
1 Week Change
+71.2%
1 Month Change
-18.9%
1 Year Change
+33.0%
Year-to-Date Change
-38.3%
From 52W High of $10.13
+170.0%
From 52W Low of $2.32
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Fulcrum Therapeutics (FULC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on FULC and similar high-potential opportunities.
Latest FULC Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, FULC has a neutral consensus with a median price target of $4.00 (ranging from $2.00 to $12.00). The overall analyst rating is Buy (7.1/10). Currently trading at $6.25, the median forecast implies a -36.0% downside. This outlook is supported by 3 Buy, 3 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Matthew Harrison at Morgan Stanley, projecting a 92.0% upside. Conversely, the most conservative target is provided by Tazeen Ahmad at B of A Securities, suggesting a 68.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FULC Analyst Ratings
3
Buy
3
Hold
1
Sell
FULC Price Target Range
Low
$2.00
Average
$4.00
High
$12.00
Current: $6.25
Latest FULC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FULC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Upgrade | $10.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Andrew Fein | Neutral | Reiterates | $4.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andrew Fein | Neutral | Reiterates | $4.00 |
| Nov 14, 2024 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $4.00 |
| Sep 13, 2024 | HC Wainwright & Co. | Andrew Fein | Neutral | Downgrade | $4.00 |
| Sep 13, 2024 | RBC Capital | Gregory Renza | Sector Perform | Downgrade | $4.00 |
| Sep 12, 2024 | B of A Securities | Tazeen Ahmad | Underperform | Downgrade | $2.00 |
| Sep 12, 2024 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $4.00 |
| Sep 12, 2024 | Stifel | Dae Gon Ha | Hold | Downgrade | $3.00 |
| Sep 12, 2024 | Cantor Fitzgerald | Kristen Kluska | Neutral | Downgrade | $0.00 |
| Sep 9, 2024 | B of A Securities | Tazeen Ahmad | Neutral | Upgrade | $10.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $17.00 |
| Jul 10, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $23.00 |
| May 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $23.00 |
| May 14, 2024 | Oppenheimer | Matthew Biegler | Outperform | Maintains | $14.00 |
| May 14, 2024 | Goldman Sachs | Corinne Jenkins | Buy | Upgrade | $15.00 |
| May 14, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $17.00 |
| May 13, 2024 | Goldman Sachs | Corinne Jenkins | Buy | Upgrade | $15.00 |
| Mar 13, 2024 | RBC Capital | Gregory Renza | Outperform | Initiates | $14.00 |
| Feb 28, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $17.00 |
Fulcrum Therapeutics Inc. (FULC) Competitors
The following stocks are similar to Fulcrum Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
FULC
Fulcrum Therapeutics
mkt cap
356.26M
Fulcrum Therapeutics Inc. (FULC) Financial Data
Fulcrum Therapeutics Inc. has a market capitalization of $351.41M with a P/E ratio of 0.0x. The company generates $80.00M in trailing twelve-month revenue with a -0.6% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -13.0% and return on equity of -0.2%.
Valuation Metrics
Market Cap
$351.41M
Enterprise Value
$155.58M
P/E Ratio
0.0x
PEG Ratio
-5.3x
Price/Sales
4.4x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-13.0%
Net Margin
-0.6%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+67.2%
Current Ratio
28.7x
Debt/Equity
3.5x
ROE
-0.2%
ROA
-2.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Fulcrum Therapeutics Inc. (FULC) Business Model
About Fulcrum Therapeutics Inc.
What They Do
Develops therapies for genetically defined diseases.
Business Model
The company focuses on gene regulation to create therapies for rare genetic disorders, generating revenue through the development and commercialization of its therapeutic candidates targeting conditions like fragile X syndrome and muscular dystrophy.
Additional Information
Founded in 2015 and based in Cambridge, Massachusetts, Fulcrum Therapeutics is dedicated to precision medicine, leveraging insights into genetic mechanisms to address significant unmet clinical needs. Its innovative approach in epigenetic modulation positions it as a key player in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
45
CEO
Mr. Alexander C. Sapir
Country
United States
IPO Year
2019
Website
www.fulcrumtx.comFulcrum Therapeutics Inc. (FULC) Latest News & Analysis
Latest News
Quick Summary
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will participate in upcoming conferences, focusing on developing therapies for genetically defined rare diseases.
Why It Matters
Fulcrum Therapeutics' conference participation may signal upcoming developments or partnerships, influencing investor sentiment and stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fulcrum Therapeutics (Nasdaq: FULC) granted non-statutory stock options to two new employees under its 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq regulations.
Why It Matters
Fulcrum Therapeutics is expanding its team, potentially enhancing innovation and productivity, which could positively impact future growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fulcrum Therapeutics, Inc. (FULC) held its Q1 2025 earnings call, providing financial results and updates on company performance. Further details can be found in the transcript.
Why It Matters
Fulcrum Therapeutics' Q1 2025 earnings call reveals financial performance, strategic direction, and potential catalysts that can influence stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
21 days ago
Quick Summary
Enrollment in the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease is complete, and the 20 mg dose cohort has been initiated.
Why It Matters
Completion of enrollment in the PIONEER trial's 12 mg cohort signals progress for pociredir in treating sickle cell disease, potentially boosting its market value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fulcrum Therapeutics will release its Q1 2025 financial results on May 1, 2025, before market open, followed by a conference call at 8:00 a.m. ET for updates on corporate developments.
Why It Matters
Fulcrum Therapeutics' upcoming financial results and conference call could reveal key insights into its performance and strategic direction, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
2 months ago
Quick Summary
Fulcrum Therapeutics will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 11, 2025, at 8:40 am ET.
Why It Matters
Management's participation in a prestigious healthcare conference signals potential investor interest and insights into Fulcrum's pipeline, which could impact stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FULC Stock
What is Fulcrum Therapeutics Inc.'s (FULC) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Fulcrum Therapeutics Inc. (FULC) has a median price target of $4.00. The highest price target is $12.00 and the lowest is $2.00.
Is FULC stock a good investment in 2025?
According to current analyst ratings, FULC has 3 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $6.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FULC stock?
Wall Street analysts predict FULC stock could reach $4.00 in the next 12 months. This represents a -36.0% decrease from the current price of $6.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fulcrum Therapeutics Inc.'s business model?
The company focuses on gene regulation to create therapies for rare genetic disorders, generating revenue through the development and commercialization of its therapeutic candidates targeting conditions like fragile X syndrome and muscular dystrophy.
What is the highest forecasted price for FULC Fulcrum Therapeutics Inc.?
The highest price target for FULC is $12.00 from Matthew Harrison at Morgan Stanley, which represents a 92.0% increase from the current price of $6.25.
What is the lowest forecasted price for FULC Fulcrum Therapeutics Inc.?
The lowest price target for FULC is $2.00 from Tazeen Ahmad at B of A Securities, which represents a -68.0% decrease from the current price of $6.25.
What is the overall FULC consensus from analysts for Fulcrum Therapeutics Inc.?
The overall analyst consensus for FULC is neutral. Out of 14 Wall Street analysts, 3 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $4.00.
How accurate are FULC stock price projections?
Stock price projections, including those for Fulcrum Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 1:56 PM UTC